Knikord
12/12/22 21:42
Ha respondido al tema
Novavax (NVAX): Un Nuevo Comienzo
Novavax is also evaluating a COVID-19-influenza combination (CIC) vaccine candidate in a phase I/II study. The CIC vaccine combines NVX-CoV2373, its authorized protein-based COVID vaccine, and its investigational influenza vaccine in a single formulation. In October, Novavax announced top-line data from this study which demonstrated the CIC vaccine was feasible and immunogenic. The immune responses were comparable to the standalone influenza vaccine candidate and standalone NVX-CoV2373 formulations. Novavax expects to begin a confirmatory phase II study evaluating this vaccine by this year’s end.